Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest CSL Limited Stories

2013-09-23 08:28:45

Approximately 11 million doses were delivered; First US supplier to complete 2013-14 seasonal influenza vaccine shipping KING OF PRUSSIA, Pa., Sept. 23, 2013 /PRNewswire/ -- CSL Biotherapies, Inc. announced today it has finalized shipment of 11 million doses of AFLURIA ®, its seasonal influenza vaccine for the 2013-2014 season. Completion of the 2013-14 shipping campaign will ensure that healthcare providers using AFLURIA® are able to conduct their immunization programs as...

2013-09-03 12:26:21

Larger Vial Size Is Another Convenience Offering for People Managing Primary Immunodeficiency with Hizentra KING OF PRUSSIA, Pa., Sept. 3, 2013 /PRNewswire/ -- CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a 10 g (50 mL) vial size for Hizentra®, Immune Globulin Subcutaneous (Human). Hizentra, the first and only 20 percent subcutaneous immunoglobulin therapy, keeps serum immunoglobulin G (IgG) levels consistent week to week to help protect...

2013-08-13 12:26:33

Designation Recognizes Kcentra as an Important New Advance for Urgent Reversal of Warfarin in Adult Patients with Acute Major Bleeding while Improving Patient Access KING OF PRUSSIA, Pa., Aug. 13, 2013 /PRNewswire/ -- CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment (NTAP) for Kcentra(TM) (Prothrombin Complex Concentrate [Human]) for use in the inpatient hospital setting for the urgent reversal of...

2013-08-06 20:24:01

In the news release, CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers, issued 06-Aug-2013 by CSL Biotherapies, Inc. over PR Newswire, we are advised by the company that the third paragraph, first sentence, should read "11 million doses" rather than "10 million doses" as originally issued inadvertently. The complete, corrected release follows: CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers Approximately 11...

2013-08-06 16:29:30

Approximately 11 million doses to be delivered within 2 months KING OF PRUSSIA, Pa., Aug. 6, 2013 /PRNewswire/ -- CSL Biotherapies, Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started. "Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before," said Dr. Marie Mazur, Head of Worldwide Commercial Operations, Influenza....

2013-07-03 12:23:55

Recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- CSL Behring today presented Phase I data of their recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam. (Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO ) CSL Behring, in collaboration with its parent company, CSL Limited (ASX:...

2013-07-03 12:23:53

Recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- CSL Behring today presented a population pharmacokinetic model for recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam. The model confirms earlier results from the first-in-human dose escalation trial, which demonstrated improved pharmacokinetics of rIX-FP, with...

2013-07-03 08:25:12

Results of Phase I/II PROLONG-9FP trial program also demonstrate efficacy in treatment of bleeding episodes and improved pharmacokinetics of rIX-FP compared to current treatment options; recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- Data presented by CSL Behring today showed clinical efficacy of a once-weekly dosing regimen of recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP). Results of the study...

2013-07-02 12:29:48

Pharmacokinetic results indicate rVIII-SingleChain may have advantages over multi-chain rFVIII AMSTERDAM, July 2, 2013 /PRNewswire/ -- CSL Behring today announced that pharmacokinetic results for its novel investigational recombinant coagulation single-chain factor VIII (rVIII-SingleChain) showed improved half-life over octocog alfa (the comparator). It also demonstrated a safety and efficacy profile that supports advancement to late-stage clinical development. The data were...

2013-06-27 08:30:58

Studies will feature research on novel investigational recombinant factor VIIa, VIII and IX therapies for hemophilia A and B KING OF PRUSSIA, Pa., June 27, 2013 /PRNewswire/ -- CSL Behring today announced it will present study data from three ongoing clinical trial programs evaluating the Company's novel recombinant factor VIIa (rVIIa-FP), VIII (rVIII-SingleChain) and IX (rIX-FP) agents for people with hemophilia A and B with and without inhibitors. The data will be presented at the...